Auris Medical Provides Update on Tinnitus Drug Development Strategy
April 25, 2019 09:00 ET
|
Auris Medical AG
Hamilton, Bermuda, April 25, 2019 (GLOBE NEWSWIRE) -- Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical...
Auris Medical Receives Positive Nasdaq Listing Determination
April 15, 2019 09:00 ET
|
Auris Medical AG
Hamilton, Bermuda, April 15, 2019 (GLOBE NEWSWIRE) -- Hamilton, Bermuda, April 15, 2019 – Auris Medical Holding Ltd. (Nasdaq: EARS), a clinical-stage company dedicated to developing therapeutics...
Auris Medical Announces Randomization of First Dose Cohort in AM-201 Phase 1b Proof-of-Concept Study
March 29, 2019 09:00 ET
|
Auris Medical AG
Hamilton, Bermuda, March 29, 2019 - Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology...
Auris Medical Announces 20-F Filing
March 14, 2019 21:48 ET
|
Auris Medical AG
Zug, Switzerland, March 15, 2019 (GLOBE NEWSWIRE) -- March 14, 2019 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important...
Auris Medical Announces 20-F Filing
March 14, 2019 17:30 ET
|
Auris Medical AG
Zug, Switzerland, March 14, 2019 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology...
Auris Medical Provides Business Update and Reports Fourth Quarter and Full Year 2018 Financial Results
March 14, 2019 07:00 ET
|
Auris Medical AG
Phase 1 trial confirmed superior bioavailability of intranasal betahistine as well as good safety and tolerability Intranasal betahistine program progressing towards proof-of-concept studies in...
Auris Medical Announces Publication of AM-111 Phase 3 Results in Peer-Reviewed Scientific Journal
March 11, 2019 08:50 ET
|
Auris Medical AG
Zug, Switzerland, March 11, 2019 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology...
Auris Medical to Report Fourth Quarter and Full Year 2018 Financial Results and Provide Business Update on Thursday, March 14, 2019
March 07, 2019 08:00 ET
|
Auris Medical AG
Zug, Switzerland, March 07, 2019 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology...
Auris Medical Announces Receipt of Nasdaq Notice
February 08, 2019 17:00 ET
|
Auris Medical AG
Hearing Requested to Present Compliance Plan Zug, Switzerland, February 8, 2019 - Auris Medical Holding AG (Nasdaq: EARS), a clinical-stage company dedicated to developing therapeutics that...
Auris Medical Announces Full Repayment of Hercules Loan Facility
February 01, 2019 07:30 ET
|
Auris Medical AG
Zug, Switzerland, February 1, 2019 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology...